drugset
drugset / Trial / NCT02207530

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT02207530 ↗

Phase 2 Completed 112 enrolled AstraZeneca PRA Health Sciences · collab
NaSingle-groupOpen-labelTreatment

Summary

Primary Objective: To assess the efficacy of MEDI4736 monotherapy in terms of ORR

Timeline

Start
2014-10-23
Primary completion
2016-09-26
Completion
2020-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody — —

Indications

head and neck squamous cell carcinoma